Mirdametinib Gains FDA Nod for NF1-PN
The FDA approved mirdametinib (Gomekli) for adults and children 2 years and older with neurofibromatosis type 1 (NF1) and symptomatic plexiform neurofibromas (PN) that are not resectable surgically.
Next-Generation Skin Drug Delivery: Artificial Intelligence Solutions for Enhanced Therapeutic Precision and Barrier Navigation
The article explores how artificial intelligence (AI) is transforming transdermal drug delivery systems (TDDS), offering innovative solutions to traditional challenges in drug administration. TDDS provides advantages over conventional oral and injectable methods by bypassing liver metabolism and enabling controlled drug release, but faces limitations due to the skin’s natural barrier properties.
FDA Approved Antibiotic Combats Complex Infections With Limited Treatment Options
The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™, a new antibiotic combination developed to treat complicated intra-abdominal infections caused by drug-resistant bacteria. This approval marks a significant step forward in combating antimicrobial resistance (AMR), a growing global health concern. EMBLAVEO™ is specifically designed to target bacteria that have become resistant to many existing antibiotics, offering a much-needed treatment option for patients facing limited choices in managing severe infections.
Understanding Diabetic Crises: Prevalence and Costs in Low-Income Nations
Diabetic emergencies remain a significant healthcare challenge in developing countries, presenting a complex intersection of medical, social, and economic issues. This systematic review highlights the concerning prevalence and impact of acute diabetic complications in resource-limited settings.
Comparing Single-Inhaler Therapy to Traditional Triple Therapies in Adults with Uncontrolled Asthma: A Comprehensive Meta-Analysis
This systematic review and meta-analysis investigated the effectiveness of triple therapy combinations for treating uncontrolled asthma in adults, with a particular focus on comparing a single inhaler containing beclometasone, formoterol, and glycopyrronium (BDP/FOR/GLY) against other triple therapy options.
